The AI Value Gap and Why Validation is a Practical First Win for Life Sciences

Got story updates? Submit your updates here. ›

While many AI conversations revolve around regulated industry transformation, the question is where to actually start in a way that does not break trust, budgets or regulatory limits. In life sciences, the fastest and most repeatable wins are showing up in FDA-oriented computer system validation (CSV) or computer software assurance (CSA), which refers to the process of validating the software used in GxP manufacturing and quality operations. This trend is highly unusual when you consider the broader AI value gap, as AI adoption continues to surge despite the fact that very few organizations are achieving measurable impact.

Why it matters

AI gets deployed first as experimental pilots and use cases that don't map cleanly onto controlled, auditable workflows. Validation is an exception, as the work is heavy on document volume and frequent auditing, making it a practical entry point for enterprise AI because it is exactly where AI can create value without turning teams into unwilling test pilots. However, in order to ensure measurable impact with AI validation, organizations must ensure there is human-in-the-loop governance to protect proprietary IP, control confidential data usage, and avoid dependence on tools that may change pricing or privacy over time.

The details

While validation is not conceptually difficult, it is labor-intensive, including assembling documents, keeping them consistent, and organizing evidence across systems. When AI is implemented as an assistant to the process, not a replacement for it, validation-focused automation can improve drafting and structuring of validation documents, mapping and consistency checks, and retrieval and reuse across controlled documentation. The value shows up as recovered time, with work that once took 40-80 hours being done in minutes.

• The trend of AI being used for validation in life sciences has been emerging over the past few years.
• McKinsey reports that about 80% of companies use generative AI in at least one function, but only around 40% report EBIT impact from AI as of 2026.

What they’re saying

What’s next

As more life sciences organizations explore using AI for validation processes, it will be important to monitor the long-term impact on cycle times, rework, defect rates, and audit retrieval performance to prove the value of this approach.